Stereotactic Ablative Radiation Therapy: A New Approach for Treating Complex Bulky Tumors
-
By
-
Jun Yang
-
Weisi Yan
-
Qiuxia Lu
-
Weihua Qi
-
Junqi Song
-
Liangfu Han
-
Waleed F. Mourad
-
Jiyuan Yang
-
Xiaodong Wu
-
July 1, 2026
Clinical Scorecard: Stereotactic Ablative Radiation Therapy: A New Approach for Treating Complex Bulky Tumors
At a Glance
| Category | Detail |
|---|
| Condition | Bulky tumors |
| Key Mechanisms | Stereotactic Centralized Ablative Radiation Therapy (SCART) framework for ultra-heterogeneous radiotherapy (UHRT) |
| Target Population | Patients with bulky tumors (≥5 cm) not amenable to surgical resection |
| Care Setting | Oncology radiotherapy |
Key Highlights
- SCART allows for targeted high-dose delivery within the tumor core while preserving surrounding normal tissue.
- The approach is designed for large, irregular, or anatomically constrained tumors.
- Early clinical experience suggests technical feasibility in selected patients.
Guideline-Based Recommendations
Diagnosis
- Identify bulky tumors typically ≥5 cm in maximum dimension.
Management
- Utilize SCART for patients with locally advanced tumors, oligoprogressive lesions, recurrent disease, or symptomatic bulky lesions.
Monitoring & Follow-up
- Prospective studies needed to define patient selection, dose ranges, and response patterns.
Risks
- Consider proximity to organs at risk and prior radiation exposure when planning treatment.
Patient & Prescribing Data
Patients with ECOG performance status 0–2 and adequate baseline organ function.
SCART is not intended for small tumors or diffuse disease without a dominant lesion.
Clinical Best Practices
- Define a central SCART treatment volume (STV) within the gross tumor volume (GTV).
- Prescribe treatment using a core-to-periphery dose ratio (Rcp).
- Restrict stereotactic apertures to the STV at each beam angle.
Related Resources & Content
